Drug intelligence / Profile preview

The-15 series

Development stage
Preclinical
Lead developer
Thena Biotech
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous
01

Overview

The-15 series (also written as THE-15 series) is a preclinical-stage booster compound series being developed by Thena Biotech. It is designed to enhance the efficacy of targeted chemotherapeutic and immunotherapy approaches. The broader platform utilizes human heavy-chain ferritin (HFt) nanocages to selectively deliver bioactive peptides (BAPs) to tumor cells expressing CD71 (transferrin receptor 1). By targeting CD71, which is highly overexpressed in various solid and hematological cancers, the platform achieves receptor-mediated cell internalization, allowing for localized activation and release of therapeutic payloads in the tumor microenvironment while sparing healthy tissues.

Beyond the preview

Go deeper on The-15 series.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on The-15 series.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call